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INTEGRATED REGIMEN THERAPEUTIC (POLYBIOLOGIC-CHEMO-
THERAPY) FOR MELANOMA ADVANCED
S. Vitello a, E. Triglia a, G. Scuderi b, M. Mangione a. aU.O. Oncologia
Medica, Osp. S.Elia Caltanissetta, Italy. bU.O. Dermatologia, Osp. S.Elia
Caltanissetta, Italy
The systemic therapy of advanced melanoma is one the most
frustrating task for the medical oncologist, in fact the treatment
yields few durable remission and minimal impact on survival
(<6 months). The response rate to 50–60% with integrated treat-
ment, but with more toxicity than chemotherapy regimen alone.
In our structure we have adopted an integrated regimen thera-
peutic (polybiologic-chemotherapy),repeated every 28 d:
Fotemustine 100 mg/m2 e.v. days 1,8
Cisplatin 40 mg/m2 e.v. days 1,2
Interleukin-2 6,000,000 s.c. days 4,5,6,16,17,18
Interferon-alfa 6,000,000 i.m. days 8,10,12,14
Interferon-alfa 3,000,000 i.m. days 4,6,16,18
We treated, consecutively from February 2006 to november
2007, 14 pts: 8 men/6 women, median age 61, range 32–68; 6 pts
with metastases to sites visceral, 4 without, 2 pts with
unresectable brain metastases, 2 pts with metastases visceral
and brain.
After 4 cycle of therapy the results are encouraging: 7 R.O.,
equal to 50% of total the pts treated. In the pts we are continued
therapy for 4 cycle still.
The most common side effects were vague symptoms, such as
malaise, fatigue, chills and fever.All of which were limited
to WHO grades 1 and 2. None of the pts required an inter-
ruption in treatment or was hospitalised during the treatment
period.
The duration of response has been >7 months, with range
5–14+.
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